Clinical services and drug development company Emyria Ltd (ASX:EMD) has made a strategic change to its board to bolster its clinical service growth in mental health.
Dr Mohit Kaushal, a renowned figure in clinical transformation and digital health, has been appointed as a non-executive director — a decision that underscores Emyria’s commitment to transforming mental health care by integrating state-of-the-art, multidisciplinary clinics alongside proprietary therapy development.
Strong track record
The new director brings a track record in scaling tech-integrated clinical services, directly supporting Emyria’s mission to lead the delivery and development of promising mental health interventions, globally.
Dr Kaushal’s noteworthy affiliations include Oak Street Health, which was acquired for US$10.6 billion by CVS Health in 2023, along with roles at Humedica, Rxante, Citiustech, Wellframe and Change Healthcare, which all culminated in high-profile acquisitions.
Callahan transition
This board change facilitates the transition of Matthew Callahan from a company director to an unpaid advisory role where he will continue to provide strategic support for Emyria. Callahan is leaving the board due to other commitments but remains a significant shareholder.
Emyria CEO Dr Michael Winlo said, “Matt's influence has been invaluable for Emyria. We thank him for his services as a director of Emyria and are grateful to continue benefiting from his advisory role.
"We’re thrilled to introduce Dr Kaushal to our team reflecting our dedication to establish a global leadership position in the delivery and development of pioneering mental health solutions. Mo brings a wealth of experience and skills in clinical transformation, digital health and investment that closely aligns with Emyria’s future growth ambitions.”
Innovative approach
As the global demand for mental health services rises, innovative new approaches including psychedelic-assisted therapy are gaining interest.
The recent landmark decision by Australia to legalise the use of MDMA and psilocybin for PTSD and treatment-resistant depression has created a unique opportunity for Emyria to lead the psychedelic-assisted therapy landscape, harnessing its strengths in clinical service delivery, real-world data collection, and therapy development.
Emyria has a focus on revolutionising patient outcomes in neuroscience and mental health via:
- Clinical service delivery: With Emerald Clinics, and the recent acquisition of the Pax Centre, a leading psychological trauma center, Emyria delivers evidence-based and emerging therapies for mental health and other unmet needs.
- Proprietary real-world data (RWD): Through its advanced data platform powered by Palantir, Emyria collects robust and ethically sourced Real-World Data to improve its care models and support its distinct therapy and drug development initiatives.
- Drug discovery and development: Guided by its RWD, Emyria is developing several proprietary Ultra-Pure cannabinoid dose forms and advancing them toward registration. In parallel, it is establishing one of the world's largest libraries of MDMA-like compounds in partnership with the University of Western Australia.